The fact that knockdown of DDIT3 in CD34+ cells from MDS cases restores erythroid differentiation, suggests that DDIT3 could represent a potential therapeutic target for the treatment of patients, particularly those with anemia. This evidence concerns the gene CD34 and myelodysplastic syndrome.